Keytruda Resistant TIL and Tumor co-culture – IMMUNE 3D



Tumor infiltrating lymphocytes (TILs) are immune cells that have migrated into the tumor environment in order to attach cancer cells. TILs are comprised of immune sub-populations that  play various roles in the immune-tumor interactions.  TILs are removed from a patient’s tumor and are then treated in the laboratory with substances that activate the lymphocytes to help them better kill the patient’s cancer cells (source: NCI).

IMMUNE 3D® is a physiologically relevant platform that is designed to capture the immune-tumor interactions in the presence of tumor environment cells.  This assay uses our Keytruda resistant TIL and Tumor cell line in comparison with Keytruda (anti-PD1) therapy and is run in a 24 well format.

What is the assay setup?

  1. Co-culture tumor and TIL for 24 hours in the presence of drug candidate
  2. After 24 hours harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. TIL + Tumor+ Keytruda (anti-PD1)
  2. TIL + Tumor+ <drug candidate (per dose)>
  3. TIL + Tumor
  4. TIL + Tumor + DMSO
  5. TIL
  6. Tumor

How many doses are included?

The assay is run in a 24 well plate and can accommodate up to 7 doses of the drug candidate. Each dose is a well.

What is included the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Lactate dehydrogenase (LDH) for tumor lysis
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Combination arm

Include study arms in combination with Keytruda (anti-PD1)

Flow cytometry

Study expression markers on TIL and tumors in response to drug candidates.